Yes, while maintaining cultural and contextual relevance.

A full redesign is necessary if your website has significant structural, visual, and strategic issues that hinder growth. In contrast, if the site's core design is modern but you need to improve key performance metrics like conversions, ongoing optimization through a retainer is a more suitable approach. A redesign provides a clean slate to build a new foundation, while optimization makes continuous, data-driven improvements to an existing one.

No. It supports engagement across recruitment, retention, and long-term community relationships.

No. It supports teams by informing strategy and improving responsiveness. No technology can replace authentic, human connection.

It incorporates engagement behavior and community insight rather than relying only on static demographics.

e-DICT™ is Acclinate’s proprietary engine for engagement-driven, intelligent community targeting.

Postmarketing requirements may obligate sponsors to conduct additional safety or effectiveness studies in underrepresented populations if the original trial lacked sufficient representation.

Diversity planning should begin early. Retrofitting inclusion strategies mid-trial often increases cost and complexity. Early planning improves enrollment stability and regulatory defensibility.

Equitable research improves data generalizability, strengthens labeling, increases clinician confidence, and reduces the likelihood of postapproval surprises that can affect payer coverage or prescribing patterns.

If enrollment does not meet diversity expectations outlined in diversity action plans, the FDA may request additional analyses or data. These requests can slow review cycles or create conditional approvals tied to future studies.

Regulators increasingly evaluate whether trial populations reflect real-world disease burden. Insufficient representation can trigger approval delays, labeling limitations, or postmarketing study requirements, which introduce financial and operational risk.